Geoff Martha participated in the 40th annual J.P. Morgan Healthcare conference virtually explaining key decisions, accepting responsibility for a trifecta of bad news while also signaling that all will be well in the future at the Dublin-based medtech giant.
The supply chain needs of the pharmaceutical industry are growing increasingly complex, particularly with the growth of cell and gene therapies that require timely delivery of medication components that have to be kept at stable temperatures.
A new report, Resilience in volatility: Modernizing the supply chain from Microsoft highlights factors that have stressed the supply chain over the past 18 months and how companies are responding to this crisis as they lay the groundwork to minimize the impact of global events in the future.
INVEST 2022 is going to be held March 28-30 in at the Ritz Carlton hotel in Chicago. This year, we have four new categories reflecting the pandemic-reality and how it has reshaped healthcare. Apply now for a chance to pitch LIVE in front of VC judges. Please note that companies that have pitched in the last 12 months at a MedCity event are ineligible to apply. Selected finalists will be asked to register for the conference at a reduced rate. Deadline is January 15.
By Stephanie Baum Tuesday, January 11, 2022 7:30 AM
The report, Resilience in volatility: Modernizing the supply chain, highlights three areas that Fortune 500 and mid-size companies need to address to implement technology such as machine learning, cloud computing and risk management tools to improve production and delivery.
By Arundhati Parmar Tuesday, January 11, 2022 1:34 AM
In a virtual panel discussion about public and population health at J.P. Morgan's annual conference, the CEO of Aledade shared how the quest for efficiency in a world of harried physicians' practices almost led Aledade to use a flawed ML algorithm to engage at-risk patients of those practices.
By Michael Schroeder Monday, January 10, 2022 11:43 PM
A leader in telemedicine, Teladoc's stock is on a slide. But company leaders expect that investors will come around as the company continues to grow, gain customers and retain existing patients.
By Frank Vinluan Monday, January 10, 2022 10:45 PM
Bristol Myers Squibb is partnering with Century Therapeutics, placing a $150 million bet that the biotech's technology for engineering stem cells can produce new off-the-shelf cell therapies for cancer. If the four potential programs covered under the pact reach the market, milestone payments could bring Century more than $3 billion.
Physicians Advocacy Institute, American Association of Neurological Surgeons, and Congress of Neurological Surgeons lead a coalition of physicians groups in filing an amicus curiae brief backing the American Medical Association and American Hospital Association's lawsuit opposing the dispute regulation guidelines of the No Surprises Act that went into effect January 1.
As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that give them access to in-vivo gene editing technologies. Pfizer is teaming up with Beam Therapeutics to develop new base-editing therapies while Bayer hopes to develop new medicines with the in-vivo CRISPR editing tools of Mammoth Biosciences.
Every company will eventually face an audit. Download this FREE general audit checklist to evaluate your organization and take proactive steps guaranteed to prepare you in order pass an audit when the time comes.
No comments